rs2227983
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Four tag SNPs, one CA simple sequence repeat (CA-SSR) in intron 1, one coding region SNP (R521K), and SNPs identified by resequencing in the tyrosine kinase domain of EGFR were selected to analyze their association with therapeutic outcome and survival in 84 advanced NSCLC patients treated with Gefitinib.
|
19201048 |
2009 |
rs2227983
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We determined the genotypes for R497K and intron1 (CA) n repeat genetic polymorphisms of 70 Chinese patients with advanced non-small cell lung cancer.
|
17597605 |
2007 |
rs1057519861
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.
|
31345012 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In patients with tissue T790M-positive NSCLC, an absence of detectable plasma T790M at the baseline is associated with longer PFS, which may be attributed to a lower disease burden.
|
31769875 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
|
31601525 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Targeting L858R/T790M/C797S mutant EGFR is a major challenge in the new-generation EGFR tyrosine kinase inhibitors development for conquering drug resistant NSCLC.
|
31787359 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
|
31696302 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
|
31557536 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
|
31841714 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Olmutinib was approved in South Korea in May 2016 for the treatment of patients suffering from locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
|
31788977 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This retrospective study used 47 DNA samples extracted from NSCLC biopsies that previous NGS identified as: 29 harboring EGFR and T790M resistance mutations, 11 EGFR-activating mutation without T790 M and 7 wild-type EGFR.
|
31836323 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Uncommon EGFR mutation showed a significantly lower incidence of acquired T790M mutation and benefited significantly less from subsequent osimertinib treatment than common EGFR mutations in patients with advanced NSCLC.
|
31786475 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Osimertinib (AZD9291), a third-generation, mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for patients who have non-small-cell lung cancer (NSCLC) with activating EGFR mutations or those harboring a resistant T790M mutation.
|
31821539 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Coexisting mutations in tumor tissue before EGFR-TKI treatment may contribute to the emergence of cell clones responsible for development of T790M-dependent or T790M-independent TKI resistance in patients with EGFR-mutated NSCLC.
|
31710890 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IGF1R activation could occur following treatment with osimertinib in EGFR-mutant NSCLC with T790M mutation, and might be one of the mechanisms underlying osimertinib resistance.
|
31758670 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>Objective:</i> ASTRIS is a large real-world, open-label, multinational clinical study of osimertinib in patients with epidermal growth factor receptor (EGFR) T790M mutation-positive advanced non-small cell lung cancer (NSCLC) who have previously received a tyrosine kinase inhibitor (TKI).
|
31581843 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy.
|
31839416 |
2020 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
|
31751804 |
2020 |
rs1057519861
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C797S does not occur in TKI-naïve NSCLCs and provide evidence that screening for this mutation before TKIs administration may not be necessary.
|
31243697 |
2019 |
rs1057519861
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR SM NSCLC can acquire resistance to osimertinib through development of the EGFR C797S mutation.
|
31377341 |
2019 |
rs1057519861
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Collectively, compound <b>13</b>, a novel hederagenin-NO donor hybrid with a different chemical structure from those of the current FDA-approved EGFR-targeted anti-NSCLC drugs, may be a promising lead compound for the treatment of NSCLC expressing gefitinib-resistant EGFR with a T790 M mutation or osimertinib-resistant EGFR-LTC with an L858R/T790M/C797S mutation.
|
31718182 |
2019 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study.
|
31442277 |
2019 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer.
|
31581004 |
2019 |
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations.
|
31289574 |
2019 |